Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression

NCT03193788 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT03193788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03193788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression
Lead sponsor
Asan Medical Center
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 2017
Completion date
June 30, 2020
Enrollment
74 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, transitional cell carcinoma, ureter cancer